scope
chapter
goal
gene
therapi
introduct
gene
human
somat
cell
therapeut
purpos
success
gene
therapi
therefor
depend
effici
therapeut
gene
transfer
patient
target
tissu
mani
case
virus
exploit
gene
transfer
purpos
particular
gene
transfer
vector
deriv
adenovirus
adenovir
vector
often
use
achiev
reviev
see
reason
adenovir
vector
effici
transfer
gene
mani
differ
cell
type
propag
welldefin
product
system
high
yield
stabl
make
purif
longterm
storag
possibl
therebi
make
pharmaceut
product
feasibl
contribut
focu
product
system
clinic
lot
adenovir
vector
particular
attent
vill
paid
gener
use
complement
cell
line
carri
el
gene
particular
emphasi
cell
line
develop
prevent
gener
replicationcompet
adenoviru
rca
propag
eldelet
adenovir
vector
addit
safeti
issu
respect
use
cell
line
make
clinic
grade
materi
address
human
adenoviru
isol
first
time
cultur
adenoid
tissu
sinc
differ
serotyp
isol
variou
tissu
excret
human
serotyp
obtain
immunocompromis
individu
serotyp
defin
basi
immunolog
distinct
judg
quantit
neutral
anim
antisera
hors
rabbit
neutral
show
certain
degre
crossreact
two
virus
distinct
serotyp
assum
hemagglutinin
unrel
shown
lack
crossreact
hemagglutinationinhibit
ii
substanti
biophys
biochem
differ
dna
exist
human
adenovirus
subdivid
six
differ
group
af
base
mainli
differ
hemagglutin
restrict
enzym
analysi
dna
homolog
adenovirus
found
associ
differ
diseas
pattern
see
eg
addit
human
adenovirus
differ
serotyp
isol
variou
anim
speci
adenovirus
possess
dna
molecul
surround
capsid
consist
essenti
hexon
pentonbas
fiber
protein
virion
icosahedr
symmetri
depend
serotyp
diamet
nm
well
character
adenoviru
serotyp
linear
doublestrand
dna
genom
approxim
base
pair
fig
adenovirus
genom
size
rang
kb
genom
contain
end
ident
invert
termin
repeat
itr
approxim
base
pair
exact
length
depend
serotyp
viral
origin
replic
within
itr
exactli
genom
end
sequenc
requir
encapsid
viral
genom
locat
region
approxim
bp
downstream
left
itr
structur
adenovir
genom
describ
basi
adenoviru
gene
express
follow
infect
human
cell
call
earli
e
late
l
accord
whether
transcript
region
take
place
prior
onset
dna
replic
infect
target
cell
start
interact
fiber
receptor
surfac
cell
mani
adenovirus
use
coxsackieadenoviru
receptor
car
present
cell
surfac
integrin
act
secondari
receptor
bind
viral
pentonbas
protein
subsequ
viru
intern
receptormedi
endocytosi
adenovirus
escap
endocyt
vesicl
receptosom
virtu
chang
configur
virion
surfac
due
low
ph
vesicl
consequ
viru
particl
releas
cytoplasm
cell
degrad
dna
end
nucleu
complex
histon
protein
form
may
attach
nuclear
matrix
replic
adenoviru
dna
usual
integr
host
cell
chromosom
dna
remain
episom
extrachromosom
unless
transform
tumorigenesi
occur
indic
product
adenoviru
infect
divid
two
distinct
phase
earli
late
phase
earli
phase
socal
earli
gene
el
adenoviru
express
prepar
host
cell
viru
replic
late
phase
actual
viral
dna
replic
product
viral
structur
protein
take
place
lead
format
new
viral
particl
adenoviru
replic
requir
hostcel
viral
protein
see
review
cellular
protein
need
replic
nuclear
factor
ii
iii
involv
initi
viral
dna
replic
elong
well
increas
effici
replic
adenoviru
dna
replic
start
express
immediateearli
el
gene
el
region
compris
two
differ
transcript
unit
ela
elb
main
function
ela
gene
product
induc
quiescent
cell
enter
cell
cycl
resum
cellular
dna
synthesi
ii
transcript
activ
elb
gene
earli
region
ela
region
encod
two
major
rna
product
gener
one
transcript
unit
differ
size
due
altern
sphcing
rna
encod
acid
protein
amino
acid
respect
adenoviru
phosphoryl
protein
present
nucleu
cell
addit
lytic
infect
mrna
lo
ii
produc
protein
found
essenti
adenovir
replic
function
protein
yet
resolv
elb
region
code
one
mrna
translat
two
protein
molecular
weight
adenoviru
kda
elb
protein
assist
ela
redirect
cellular
function
allow
viral
replic
elb
protein
form
complex
open
read
frame
protein
local
nucleu
main
function
inhibit
synthesi
host
protein
facilit
express
viral
gene
addit
also
block
tumorsuppressor
protein
therebi
inhibit
apoptosi
elb
protein
import
quench
cytotox
effect
target
cell
induc
ela
protein
antiapoptot
function
similar
human
protein
import
prevent
prematur
death
host
cell
viru
life
cycl
complet
mutant
virus
incap
express
elb
geneproduct
exhibit
shorten
infect
cycl
accompani
excess
degrad
host
cell
chromosom
dna
jgphenotyp
enhanc
cytopath
effect
cytphenotyp
region
encod
three
differ
protein
function
viral
dna
replic
adspecif
dna
polymeras
precursor
termin
protein
ptp
dnabind
protein
dnabind
protein
encod
gene
bind
singlestrand
dna
involv
unwind
duplex
dna
might
also
involv
regul
transcript
precursor
termin
protein
ptp
dna
polymeras
present
heterodim
encod
region
ptp
attach
adenovir
dna
cleav
viral
proteas
late
infect
function
protect
dna
nucleolyt
breakdown
attach
adenovir
dna
nuclear
matrix
may
local
viral
genom
area
nucleu
high
concentr
replic
transcript
factor
present
polymeras
involv
synthesi
new
dna
strand
none
product
requir
viru
replic
howev
play
import
role
viru
multipl
vivo
sinc
protect
virusinfect
cell
erad
host
immun
respons
review
sever
differenti
splice
mrna
synthes
region
infect
six
differ
polypeptid
identifi
infect
cell
protein
involv
modul
gene
express
viral
replic
mainli
interact
host
cell
protein
involv
posttranscript
process
increas
viral
late
protein
synthesi
facilit
cytoplasm
accumul
mrna
encod
protein
expans
pool
late
rna
nucleu
like
influenc
splice
addit
protein
form
complex
vith
elb
protein
select
increas
rate
export
viral
late
mrna
nucleu
complex
locat
socal
viral
inclus
bodi
region
viral
dna
replic
viral
late
gene
transcript
rna
process
occur
protein
either
alon
complex
elb
protein
bind
cellular
protein
therebi
block
potenti
activ
transcript
tumorsuppress
gene
orfl
sequenc
relat
dutpas
enzym
hypothes
gene
role
stimul
quiescent
cell
protein
bind
protein
phosphatas
vhich
result
hypophosphoryl
protein
includ
adenoviru
el
protein
perhap
limit
cytotox
effect
el
may
lead
product
infect
also
line
observ
mutant
effect
wildtyp
virus
kill
nonpermiss
rodent
cell
also
induc
apoptosi
transform
cell
like
cell
modul
activ
cellular
transcript
factor
may
subsequ
activ
cellular
gene
vhich
import
phase
function
orfl
lytic
infect
less
clear
dispens
growth
viru
laboratori
cell
line
onset
dna
replic
express
late
gene
control
one
promot
switch
gene
encod
structur
compon
viru
particl
includ
penton
hexon
hexon
assembl
fiber
protein
protein
form
new
viru
particl
adenovir
dna
becom
entrap
depend
serotyp
progeni
adenoviru
particl
gener
singl
cell
adenovir
replic
caus
lysi
cell
previou
section
chapter
function
adenovir
gene
product
repuc
adenoviru
describ
extens
influenc
adenovir
protein
larg
number
cellular
function
absenc
lytic
viral
replic
adenovir
gene
may
profound
effect
cellular
function
strike
transform
adenovir
el
elb
protein
clearli
protein
interfer
vith
regulatori
mechan
cellular
prolifer
human
adenovirus
narrow
host
rang
product
infect
propag
cell
human
chimpanze
pig
cotton
rat
rodent
cell
eg
rat
except
cotton
rat
hamster
mous
bring
abort
infect
occasion
lead
transform
transform
cell
adenovir
dna
integr
genom
least
gene
viral
el
region
express
review
virus
use
studi
mainli
adenoviru
serotyp
variou
ad
serotyp
differ
abil
induc
tumor
upon
inocul
newborn
hamster
exampl
ad
type
nononcogen
wherea
highli
oncogen
howev
ad
serotyp
dna
transform
rodent
cell
cell
form
tumor
immunodefici
mice
rat
wherea
cell
oncogen
immunodefici
immunocompet
anim
correl
abil
repress
express
mhc
class
gene
cultur
rodent
cell
eg
rat
mous
hamster
human
cell
transform
ad
dna
although
human
cell
includ
fibroblast
epitheli
cell
rel
refractori
transform
adenoviru
dna
transform
human
cell
line
made
cultur
human
embryon
kidney
human
embryon
retina
human
embryon
lung
recent
human
amniocyt
describ
el
region
consist
two
transcript
unit
ela
elb
complet
morpholog
transform
region
need
ela
region
immort
rodent
cell
occasion
human
cell
albeit
low
effici
express
ela
usual
result
induct
program
cell
death
apoptosi
prevent
coexpress
elb
ela
associ
number
cellular
protein
includ
tumor
suppressor
gene
product
prb
well
cyclin
e
cyclindepend
kinas
review
protein
involv
cellcycl
control
except
regul
activ
transcript
factor
el
protein
exert
activ
initi
transcript
direct
sequencespecif
bind
dna
rather
bind
cellular
transcript
factor
elb
protein
cooper
independ
el
transform
requir
inhibit
apoptot
respons
initi
ela
elb
protein
inhibit
apoptosi
block
function
tumorsuppressor
protein
mediat
elainduc
apoptosi
elb
protein
inhibit
apoptosi
way
similar
cellular
protein
adenovir
vector
current
use
gene
therapi
delet
el
region
novel
genet
inform
introduc
el
delet
render
recombin
viru
replicationdefect
prerequisit
clinic
applic
order
abl
produc
eldelet
recombin
adenovir
vector
complement
cell
line
use
express
el
protein
adenoviru
one
main
challeng
express
suffici
level
el
protein
achiev
howev
adenoviru
el
protein
particular
ela
protein
toxic
cell
ela
profound
effect
transcript
mani
cellular
gene
lead
alter
morpholog
growth
cell
may
lead
apoptosi
exampl
report
literatur
cell
immort
transform
ela
describ
rodent
human
cell
known
whether
cell
express
ela
abl
complement
adenovir
vector
delet
ela
elb
attempt
also
made
express
el
protein
establish
cell
line
growth
establish
cell
depend
el
express
toxic
el
protein
made
difficult
isol
clone
show
stabl
express
el
protein
although
paper
report
encourag
result
best
knowledg
limit
use
cell
therefor
chapter
deal
mainli
group
elexpress
cell
use
transform
capac
adenovir
el
gene
typic
exampl
cell
line
deriv
human
embryon
kidney
hek
human
embryon
retina
human
amniocyt
advantag
use
el
immort
cell
depend
el
express
growth
therefor
level
el
express
remark
constant
time
vast
major
cell
line
made
immort
transform
primari
cell
made
studi
immort
transform
made
propag
eldelet
adenovir
vector
document
cell
line
base
el
immort
principl
made
specif
use
gene
therapi
cell
line
amniocytederiv
cell
line
cell
line
tailormad
manufactur
clinic
lot
adenovir
vector
special
attent
avoid
gener
rca
see
addit
proper
document
adequ
safeti
test
pivot
ensur
manufactur
safe
batch
adenovir
vector
cell
line
current
use
make
clinic
lot
adenovir
vector
descript
gener
given
also
perform
cell
line
product
recombin
adenoviru
well
result
safeti
genet
test
provid
major
prepar
eldelet
adenovir
vector
produc
cell
cell
line
gener
leiden
group
prof
van
der
eb
transfect
el
sequenc
adenoviru
type
primari
human
embryon
kidney
cell
aim
experi
studi
transform
potenti
adenovir
el
sequenc
dna
use
shear
adenovir
dna
precis
map
adenovir
sequenc
present
cell
line
indic
cell
line
integr
base
adenovir
dna
adenovir
vector
carri
delet
el
region
run
approxim
nt
nt
adenovir
genom
mean
substanti
sequenc
overlap
el
sequenc
present
cell
line
adenovir
vector
dna
see
fig
sequenc
overlap
may
result
homolog
recombin
sequenc
due
doubl
crossov
el
region
present
cellular
chromosom
may
end
eldelet
adenovir
vector
fig
result
viru
elposit
therefor
capabl
replic
independ
cell
contain
el
sequenc
chromosom
sever
report
describ
occurr
rca
adenovir
vector
batch
produc
cell
rca
clinic
prep
unwant
manufactur
safeti
point
view
appear
batch
chanc
process
therefor
unpredict
difficult
control
signific
problem
gmp
manufactur
particular
largescal
batch
prepar
also
unwant
safeti
point
view
upon
coinfect
cell
rca
caus
eldelet
adenovir
vector
replic
uncontrol
way
caus
shed
vector
addit
rca
shown
caus
inflammatori
respons
therefor
rca
gener
product
eldelet
adenovir
vector
circumv
strategi
prevent
rca
occurr
elimin
sequenc
overlap
el
sequenc
present
cellular
genom
adenovir
vector
potenti
hurdl
way
elb
pix
gene
regul
elb
pix
use
poli
sequenc
furthermor
pix
gene
express
upon
transfect
cultur
cell
express
present
adenovir
genom
therefor
rcafre
packag
system
consist
two
compon
adenovir
vector
delet
ela
elb
contain
pix
express
cassett
ii
cell
hne
express
ela
elb
devoid
pix
sequenc
creat
novel
cell
line
aim
use
minim
number
human
sequenc
ie
el
protein
code
sequenc
prevent
sequenc
overlap
eldelet
ad
el
promot
poli
sequenc
therefor
obtain
nonadenoviru
sourc
el
promot
replac
human
phosphoglycer
kinas
pgk
promot
see
known
housekeep
promot
poli
sequenc
isol
hepat
b
viru
construct
pigelaelb
contain
addit
ela
elb
code
region
sequenc
upstream
ela
gene
includ
ela
enhanc
element
cap
sequenc
untransl
ela
sequenc
also
retain
construct
element
includ
sinc
earlier
studi
indic
result
effici
express
ela
gene
map
construct
design
pigelaelb
present
fig
despit
remov
splice
site
posit
adenovir
genom
highli
conserv
truncat
elb
transcript
high
express
level
elb
kda
elb
kda
obtain
fact
express
elb
protein
even
higher
cell
wherea
equal
express
level
ela
observ
prevent
sequenc
overlap
el
present
cell
adenovir
vector
construct
carri
delet
complet
el
region
vector
shown
propag
effici
cell
see
found
express
pix
gene
primari
cell
select
make
new
elcompl
cell
line
human
embryon
retinoblast
choic
retinoblast
base
observ
could
transform
hamster
retin
cell
vitro
induc
retinoblastoma
follow
intraocular
inject
newborn
baboon
describ
cell
immort
rel
easili
el
human
addit
cell
deriv
cell
effici
product
recombin
adenovir
vector
easi
use
thu
provid
second
argument
use
primari
cell
sourc
primari
cell
make
novel
cell
line
primari
isol
cultur
therefor
pigelaelb
construct
transfect
primari
cell
cell
isol
describ
detail
propag
cell
passag
number
research
master
cell
bank
laid
extens
character
test
safeti
includ
steril
test
see
immort
primari
cell
el
sequenc
adenoviru
guarante
stabl
express
el
protein
cell
need
el
express
growth
ii
extern
select
marker
need
distinguish
el
express
nonexpress
cell
human
adenoviru
serotyp
taken
donor
el
sequenc
order
test
whether
cell
abl
propag
adenovir
vector
without
concomit
gener
rca
eldelet
adenovir
vector
propag
cell
cell
adenovir
vector
use
sequenc
overlap
el
sequenc
batch
vector
analyz
presenc
rca
use
cell
cultur
base
assay
describ
result
summar
tabl
clearli
indic
adenovir
vector
propag
cell
get
contamin
rca
hand
data
provid
tabl
clearli
demonstr
cell
support
rcafre
propag
el
delet
adenovir
vector
even
largescal
batch
produc
cell
test
rca
sensit
assay
infecti
unit
separ
experi
eland
vector
deriv
propag
cell
master
viru
seed
mv
prepar
passag
use
gener
virusproduct
lot
passag
unprocess
viru
harvest
vectorinfect
suspens
cultur
mv
virusproduct
lot
test
rca
brief
test
articl
frozen
thaw
assay
inocul
onto
humanlungcarcinoma
atcc
ccl
cell
line
approxim
h
inoculum
remov
cultur
refe
medium
cultur
passag
three
time
amplifi
put
rca
present
incub
time
rang
day
earli
passag
day
final
passag
cultur
examin
cytopath
effect
passag
virusproduct
scale
approxim
l
ml
volum
dilut
ml
avoid
toxic
interfer
detect
rca
test
rca
lot
test
volum
select
basi
worstcas
calcul
ensur
test
least
three
dose
equival
viru
earlier
virusproduct
studi
suggest
freezethaw
extract
would
contain
least
x
particlesml
ml
thu
least
x
particl
three
dose
equival
would
test
assum
random
poisson
distribut
rca
averag
one
rca
per
x
particl
ml
one
would
predict
probabl
detect
test
x
particl
e
chanc
test
x
particl
ml
binomi
probabl
detect
x
particl
reduc
chanc
mathemat
equival
three
independ
test
ml
ml
total
rca
detect
mv
eight
virusproduct
lot
assay
use
ratio
determin
purifi
viru
particlesinfecti
unit
virusproduct
lot
estim
averag
x
particlesml
estim
mean
probabl
detect
least
one
rca
dose
particl
virusproduct
lot
besid
directli
test
infect
cell
suspens
mv
rca
repeat
inabl
detect
rca
variou
clinic
batch
bode
well
rcafre
natur
mv
clinic
product
run
ml
mv
use
inocul
roller
bottl
rb
mean
total
ml
mv
use
clinic
lot
follow
calcul
scheme
one
rca
per
ml
mv
would
probabl
chanc
transmit
rca
prepar
singl
clinic
batch
moreov
cumul
across
eight
clinic
product
run
would
ef
x
probabl
x
chanc
transmit
rca
prepar
eight
lot
conclus
freezethaw
sampl
use
rca
test
provid
adequ
assur
detect
rca
virusproduct
lot
level
one
rca
dose
howev
test
futur
vector
lot
plan
use
clarifi
lysat
case
probabl
estim
detect
rca
base
direct
measur
viru
concentr
summari
elimin
overlap
el
sequenc
cell
eldelet
adenovir
vector
elimin
rca
construct
eldelet
adenovir
vector
number
choic
must
made
regard
structur
vector
backbon
composit
transgen
one
must
determin
size
el
delet
vill
adequ
accommod
size
transgen
addit
delet
region
need
one
must
also
decid
placement
transgen
within
genom
el
vs
orient
transgen
el
parallel
vs
el
antiparallel
final
one
must
decid
composit
transgen
term
transcript
regul
element
util
promot
polyadenyl
signal
paramet
make
construct
adenovir
vector
express
transgen
desir
level
genet
stabl
propag
well
enough
allow
highlevel
product
somewhat
empir
process
net
genom
size
vector
delet
use
transgen
orient
composit
transgen
transgen
product
affect
growath
product
vector
degre
vector
transgen
structur
effect
genom
stabil
product
illustr
experi
vector
fig
vector
contain
el
delet
transgen
introduc
el
antiparallel
orient
transgen
compos
gene
interest
flank
immediateearli
gene
promot
intron
human
cytomegaloviru
bovin
growth
hormon
polyadenyl
signal
sequenc
addit
delet
el
region
vector
delet
genet
stabil
vector
assess
serial
passag
found
unstabl
restrict
analysi
purifi
viral
dna
recov
passag
indic
viru
popul
contain
genet
variant
fig
passag
seri
proport
number
variant
appear
increas
analysi
novel
restrict
fragment
close
individu
recov
circular
viral
genom
indic
two
genet
mechan
could
account
observ
rflp
delet
transgen
express
cassett
particularli
region
hcmv
promotor
intron
two
instanc
delet
adenoviru
sequenc
ii
amplif
two
four
repeat
sequenc
region
contain
viral
packag
element
rearrang
insert
region
detect
genet
analysi
vector
led
develop
highli
stabl
vector
easili
propag
cell
suggest
genet
instabl
overcom
vector
design
necessarili
relat
use
cell
make
eldelet
adenovir
vector
human
gene
therapi
scaleabl
process
suitabl
commerci
manufactur
gmp
condit
develop
one
key
factor
develop
cellculturebas
product
process
cultur
system
particular
scale
process
need
cultur
cell
bioreactor
highli
desir
robust
scaleabl
system
suspens
growth
requir
cell
line
extrem
advantag
cell
cultur
adher
cell
suspens
cultur
suspens
growth
specif
welldefin
serumfre
media
develop
eg
excel
jrh
bioscienc
media
contain
protein
deriv
human
anim
tissu
specimen
result
mani
fewer
contamin
remov
downstream
process
also
favor
safeti
profil
respect
pathogen
might
introduc
animalhumanderiv
compon
serumfre
cultur
medium
sfmedium
support
growth
cell
densiti
x
cellsml
routin
tflask
roller
bottl
cultur
perfus
bioreactor
system
cell
densiti
cellml
easili
obtain
overview
process
product
eldelet
recombin
adenovirus
present
fig
summar
thaw
vial
expans
tflask
contain
sfmedium
done
follow
transfer
suspens
cultur
roller
bottl
roller
bottl
cultur
suffici
cell
gener
inocul
bioreactor
standard
batchwis
product
process
eg
bioreactor
half
bioreactor
work
volum
inocul
x
cellsml
grown
day
x
cellsml
dilut
x
cellsml
ad
volum
fresh
medium
seed
viru
ad
temperatur
lower
follow
harvest
day
pellet
latter
necessari
purif
process
consist
ultracentrifug
cscl
densiti
gradient
day
viru
particl
becom
suspend
util
ir
n
u
ftraf
iltrat
captur
final
product
sec
ex
figur
overview
process
product
eldelet
recombin
adenoviru
process
describ
section
chapter
cell
lysi
batch
process
robust
econom
sinc
low
cell
densiti
obtain
due
rapid
consumpt
nutrient
medium
high
cell
densiti
requir
perfus
system
use
nutrient
replac
metabolit
remov
perfus
fresh
medium
suitabl
perfus
system
obtain
hollow
fiber
modul
modul
oper
extern
bioreactor
therefor
easili
replac
malfunct
occur
hollowfib
technolog
also
opportun
viru
retent
easi
scaleup
potenti
applic
first
step
viru
isol
take
full
advantag
highdens
cultur
viru
replic
last
longer
day
enabl
util
cell
present
repeat
infect
occur
newli
releas
particl
lyse
cell
typic
exampl
bioreactor
run
present
fig
larg
part
total
produc
viru
suspens
volum
cultur
larg
enabl
purif
ultracentrifug
hollowfib
ultrafiltr
chromatographi
method
choic
viru
isol
purif
system
directli
connect
bioreactor
therebi
ensur
close
system
viru
isol
cultur
medium
captur
viru
bulk
product
purifi
util
ion
exchang
chromatographi
andor
size
exclus
chromatographi
system
obtain
product
high
puriti
infect
final
formul
done
ultrafiltr
bring
product
final
concentr
requir
buffer
similar
yield
eldelet
adenovir
vector
obtain
obtain
other
estim
scale
requir
bioreactor
celllin
stabil
calcul
follow
cell
densiti
use
viru
product
perfus
mode
x
cellml
therefor
assum
least
viru
particl
per
cell
yield
overal
expect
yield
crude
bioreactor
harvest
x
vpcell
x
x
cellml
x
vpml
optim
maximum
expect
loss
viru
particl
downstream
process
dsp
column
chromatographi
therefor
perfus
bioreactor
x
vpml
x
recoveri
x
ml
x
vp
obtain
give
x
x
vpdose
dose
assum
x
vpdose
product
develop
batch
retain
qc
archiv
purpos
patient
receiv
x
dose
therefor
use
current
develop
technolog
bioreactor
suffici
gener
materi
first
clinic
studi
howev
abl
process
develop
larger
scale
need
full
commerci
product
larger
vessel
requir
full
product
scale
expect
five
time
larger
therefor
bioreactor
expect
maximum
volum
requir
applic
singl
dose
vp
propag
cell
work
cell
bank
ampoul
contain
cell
cellml
cultur
bioreactor
would
take
cell
doubhng
reliabl
product
process
would
requir
cell
line
least
stabl
cell
doubl
shown
stabl
respect
el
express
least
cell
doubl
qc
test
cell
use
manufactur
biolog
vaccin
safeti
vaccin
biolog
manufactur
continu
cell
line
anim
human
origin
paramount
import
must
ensur
manufactur
program
qualiti
control
qc
test
appli
product
releas
human
administr
qc
test
intend
ensur
ident
product
ii
ensur
safeti
steril
product
demonstr
absenc
adventiti
microbi
agent
iii
ensur
safeti
steril
product
demonstr
absenc
adventiti
viral
agent
program
qc
test
appli
biolog
product
formal
releas
protocol
develop
respons
depart
bioanalyt
develop
releas
protocol
develop
evalu
integr
relev
compendi
literatur
preced
ii
origin
cell
line
use
product
develop
master
cell
bank
iii
sourc
qualiti
control
test
raw
materi
anim
origin
use
manufactur
iv
method
good
manufactur
practic
cgmp
manufactur
bulk
intermedi
final
product
consid
among
thing
qualiti
environ
bioprocess
conduct
method
manufactur
particular
isol
cultur
system
oper
consist
prepar
releas
protocol
prescrib
qc
test
appli
final
product
importantli
master
cell
bank
master
viru
seed
bioprocess
input
raw
materi
anim
origin
intermedi
bulk
product
develop
dovnstream
process
purif
formul
releas
protocol
specifi
test
method
volum
test
reli
upon
bacteri
broth
agar
cultur
embryon
egg
small
anim
vitro
cell
cultur
varieti
primari
continu
cell
line
mammalian
human
origin
method
well
known
sensit
detect
varieti
bacteri
viral
agent
appli
concert
provid
comprehens
sensit
analyt
approach
upon
ensur
product
safeti
recent
develop
exquisit
sensit
polymeras
chain
reaction
pcr
method
detect
agent
refractori
anim
cell
cultur
classic
propag
method
commonli
supplement
agentspecif
test
use
pcr
polymeraseenhanc
revers
transcriptas
pert
assay
gener
method
test
ensur
product
safeti
present
illustr
form
fig
develop
research
master
cell
bank
rmcb
support
manufactur
biolog
previous
describ
releas
protocol
ensur
ident
ii
steril
iii
viral
safeti
rmcb
present
tabl
ii
qc
test
conduct
contract
inveresk
research
tranent
scotland
microsaf
leiden
netherland
evid
enzymat
activ
ofrt
figur
test
method
demonstr
product
safeti
releas
protocol
research
work
cell
bank
rwcb
accord
panel
test
present
tabl
iii
qc
test
conduct
contract
inveresk
research
microsaf
test
includ
test
ident
ii
steril
iii
viral
safeti
cell
human
simian
origin
cryopreserv
vial
rwcb
obtain
crucel
merck
research
laboratori
expand
condit
cgmp
manufactur
creat
master
cell
bank
mcb
futur
manufactur
use
mcb
releas
use
propag
recombin
adenoviru
accord
releas
protocol
present
tabl
iv
preponder
qc
test
conduct
qone
biotech
glasgow
scotland
releas
protocol
rwcb
provid
persuas
demonstr
ident
ii
steril
iii
viral
safeti
mcb
releas
protocol
specifi
anim
test
small
anim
supplement
egg
safeti
test
appli
rwcb
expand
varieti
primari
continu
cell
line
use
viral
safeti
use
vitro
cell
cultur
greatli
broaden
varieti
agentspecif
test
use
pcrbase
test
biochem
test
retrovirus
human
cell
line
includ
panel
tissu
cultur
cell
line
attempt
detect
presenc
defect
adventiti
viru
requir
presenc
el
host
cell
direct
assay
revers
transcriptas
well
detect
rt
cocultiv
supernat
fluid
done
highli
sensit
pcrbase
revers
transcriptas
pbrt
assay
supplement
pcr
test
includ
tabl
v
b
tumorigen
three
tumorigen
studi
vere
carri
cell
line
result
studi
summar
tabl
vi
first
studi
nude
nunu
mice
vere
inject
subcutan
vith
cell
posit
control
anim
vere
inject
subcutan
kb
cell
kb
known
tumorproduc
cell
line
deriv
epidermoid
carcinoma
american
type
cultur
collect
studi
conduct
day
point
anim
necropsi
examin
grossli
histolog
posit
control
anim
grow
nodul
male
mice
femal
mice
receiv
cell
grow
nodul
thu
produc
posit
test
tabl
via
time
first
studi
day
durat
usual
use
subsequ
center
biolog
evalu
research
cber
food
drug
administr
suggest
observ
period
extend
day
give
time
slow
grow
tumor
appear
nontumorigen
nodul
regress
disappear
therefor
tumorigen
studi
cell
repeat
second
studi
perform
nude
nunu
mice
period
thirti
nude
mice
inject
subcutan
cell
ml
serumfre
medium
posit
control
mice
inject
subcutan
hela
cell
ml
serumfre
medium
neg
control
mice
inject
ml
medium
mice
palpat
inject
site
everi
day
nodul
found
measur
two
dimens
cell
test
arm
neg
control
arm
mice
necropsi
day
postinject
posit
control
arm
necropsi
day
postinject
gross
histolog
examin
perform
inject
site
nodul
appear
initi
day
inject
palpabl
nodul
present
subcutan
inject
site
anim
inocul
cell
postinject
day
detect
mass
disappear
inject
site
howev
sever
mice
mass
subsequ
reappear
around
day
continu
enlarg
anim
necropsi
mice
inject
cell
sacrif
day
sacrif
day
sacrif
day
actual
sacrif
day
due
tumor
size
gross
microscop
evid
tumor
tabl
vi
b
histolog
recurr
nodul
compos
sheet
larg
pleomorph
cell
numer
sometim
abnorm
mitot
figur
mass
compress
surround
tissu
invas
tumor
observ
outsid
inject
site
interpret
test
cell
posit
tumorigen
view
posit
tumorigen
result
obtain
follow
inject
cell
titrat
studi
perform
nude
mice
inject
cell
dose
cell
per
anim
mice
necropsi
day
postinject
anim
receiv
cell
palpabl
mass
inject
site
first
palpat
day
necropsi
none
anim
gross
microscop
evid
nodul
tumor
cell
collect
necropsi
time
point
two
mice
receiv
cell
palpabl
nodul
postinject
day
mass
disappear
day
recur
gross
histolog
examin
inject
site
neg
necropsi
time
point
mice
receiv
cell
anim
palpabl
nodul
day
disappear
becam
smaller
recur
grew
progress
necropsi
necropsi
mice
day
tumor
mice
sacrif
day
tumor
group
schedul
day
tumor
sacrif
day
tumor
size
tabl
vi
c
histolog
gross
featur
cell
tumor
similar
describ
previou
studi
metastat
nodul
found
thu
tumorigen
studi
cell
posit
cell
per
anim
neg
cell
per
anim
would
indic
cell
tumorigen
andor
critic
mass
tumorigen
cell
necessari
tumor
format
view
posit
tumorigen
studi
cell
oncogen
potenti
residu
dna
cell
test
nude
mice
newborn
hamster
studi
dna
isol
passag
cell
use
standard
procedur
dna
prepar
shown
high
molecular
weight
averag
size
kb
devoid
signific
protein
rna
impur
nude
mous
studi
femal
nude
nunu
mice
inject
subcutan
jlg
dna
volum
ml
neg
control
two
group
femal
mice
inject
subcutan
ml
vehicl
approxim
month
inject
mice
necropsi
examin
histolog
tumor
growth
none
mice
studi
exhibit
gross
microscop
evid
tumor
inject
site
one
treat
mous
lymphoma
distant
site
howev
nude
mice
particularli
femal
known
high
incid
spontan
lymphoma
occurr
singl
lymphoma
treat
mice
consist
spontan
incid
although
lymphoma
almost
certainli
spontan
event
polymeras
chain
reaction
pcr
studi
perform
lymphoma
dna
determin
evid
presenc
adenoviru
el
region
transform
agent
cell
studi
neg
sensit
approxim
one
copi
el
per
tumor
cell
previous
el
express
shown
necessari
maintain
transform
state
cell
like
cell
transform
el
result
pcr
analysi
support
conclus
lymphoma
spontan
event
induc
dna
second
tumorigen
studi
use
dna
cell
carri
newborn
hamster
h
birth
femal
male
hamster
total
inject
subcutan
approxim
xg
dna
volum
jll
two
group
control
hamster
mix
sex
per
group
inject
jll
vehicl
sever
pup
group
lost
due
matern
cannib
reduc
group
size
femal
male
dna
group
femal
male
control
group
femal
male
control
group
wean
hamster
palpat
weekli
basi
hamster
necropsi
approxim
month
inject
examin
grossli
histolog
tumor
growth
one
femal
hamster
control
group
die
approxim
week
inject
malign
ovarian
teratoma
evid
tumor
found
hamster
inject
dna
basi
concern
use
tumorigen
cell
substrat
produc
vaccin
includ
three
theoret
possibl
first
dna
cell
carri
put
activ
oncogen
cancercaus
mutat
could
integr
recipi
genom
produc
tumor
second
transform
protein
cell
could
transmit
result
tumor
third
adventiti
tumor
viru
may
present
could
transmit
recipi
produc
tumor
concern
residu
dna
tumorigen
cell
substrat
sever
report
demonstr
dna
extract
tumorigen
cell
line
tumor
grow
vivo
even
purifi
activ
oncogenesdo
produc
tumor
inject
anim
level
xg
dna
neg
result
obtain
dna
nude
mice
newborn
hamster
consist
find
case
studi
amount
dna
inject
jlg
repres
excess
compar
amount
residu
dna
present
dose
vaccin
produc
cell
substrat
other
calcul
pg
residu
dna
tumorigen
cell
would
equal
less
billionth
tumorproduc
dose
second
concern
transform
protein
growth
factor
consid
studi
group
signific
continu
produc
cell
continu
administr
studi
group
consid
presenc
contamin
known
growth
factor
concentr
would
found
constitut
seriou
risk
biolog
product
prepar
continu
cell
line
third
categori
concern
virus
adventiti
agent
present
potenti
risk
risk
greatest
primari
cell
use
frequent
need
newli
acquir
cell
requir
repeat
extens
test
adventiti
agent
human
diploid
cell
line
continu
tumorigen
cell
line
thoroughli
routin
test
wide
varieti
known
unknown
adventiti
agent
seri
vitro
vivo
assay
thu
provid
adequ
assur
adventiti
agent
transmit
gener
accept
abnorm
form
cell
surfac
glycoprotein
prp
prion
protein
main
infecti
agent
transmiss
spongiform
encephalopathi
like
scrapi
bovin
spongiform
encephalopathi
bse
creutzfeldtjakob
diseas
cjd
review
abnorm
form
prp
call
prp
prpre
character
remark
resist
denatur
agent
degrad
proteinas
k
prot
k
diagnost
test
take
advantag
unusu
stabil
allow
distinct
prp
prp
use
antibodi
recogn
form
ofprp
eg
human
prion
diseas
occur
sporad
acquir
inherit
form
differ
clinic
patholog
phenotyp
review
new
variant
cjd
vcjd
report
unit
kingdom
rel
young
patient
clinic
featur
differ
known
cjd
form
also
found
strain
type
prion
protein
patient
indistinguish
one
caus
bse
thu
rais
question
whether
vcjd
could
acquir
consumpt
meat
cattl
suffer
bse
possibl
transmiss
prp
bovin
human
rais
safeti
issu
cultur
cell
line
use
product
human
drug
therefor
cell
care
examin
prp
phenotyp
see
well
genotyp
found
specif
mutat
prp
gene
associ
hereditari
form
human
prion
diseas
review
furthermor
common
methioninevalin
polymorph
codon
prp
gene
appear
associ
phenotyp
variabl
suscept
sporad
iatrogen
cjd
vast
major
patient
suffer
scjd
also
vcjd
found
homozyg
wherea
patient
heterozyg
codon
strikingli
underrepres
examin
whether
prp
gene
contain
known
mutat
associ
suscept
prion
diseas
prp
gene
sequenc
sequenc
studi
genom
dna
cell
isol
use
amplifi
prp
gene
sequenc
pcr
result
pcr
product
clone
vector
prp
gene
prpcontain
clone
sequenc
baseclear
leiden
netherland
five
clone
contain
sequenc
code
methionin
prp
protein
eight
contain
valin
prp
sequenc
demonstr
heterozygos
posit
confirm
observ
result
pcr
product
also
sequenc
expect
doubl
peak
ga
observ
codon
posit
defin
valin
nucleotid
guanin
methionin
nucleotid
adenin
prp
gene
sequenc
compar
wildtyp
sequenc
publish
genbank
access
found
ident
wild
type
gene
thu
rule
possibl
cell
possess
hereditari
mutat
would
predispos
prion
diseas
sequenc
also
reveal
cell
heterozyg
methioninevalin
codon
prp
constitut
express
adult
brain
lower
level
tissu
like
liver
spleen
prp
express
also
found
varieti
rodent
human
cell
line
studi
cell
shown
cell
also
express
cellular
form
prp
valid
western
blot
analysi
prot
ktreat
protein
extract
cell
parent
cell
fail
detect
prot
kresist
form
prp
passag
cell
passag
parent
cell
addit
sequenc
prion
gene
test
presenc
abnorm
prion
protein
cell
earli
late
passag
level
cultur
serum
trypsin
batch
use
trace
see
deriv
unit
kingdom
final
possibl
adopt
cell
serumfre
suspens
bovin
sera
complet
avoid
futur
desir
abovement
characterist
make
safe
manufactur
cell
line
respect
genet
character
cell
integr
ela
elb
code
region
present
test
sequenc
analysi
done
bidirect
sequenc
pcr
fragment
gener
region
sequenc
fragment
compar
origin
pigelaelb
sequenc
construct
initi
use
transfect
mutat
delet
insert
detect
sequenc
pcr
fragment
pigelaelb
indic
genet
alter
introduc
ela
elb
region
transfect
subsequ
cultur
cell
chromosom
integr
site
plasmid
pigelaelb
determin
use
multicolor
fluoresc
situ
hybrid
meish
techniqu
combin
principl
combin
binari
ratio
label
cobra
techniqu
combin
cobramfish
use
chromosomespecif
paint
probe
human
chromosom
plasmid
probe
pigelaelb
visual
color
pigelaelb
integr
site
determin
use
cell
deriv
research
master
cell
bank
passag
number
cell
analyz
passag
number
two
hundr
fifti
metaphas
interphas
studi
pigelaelb
integr
detect
chromosom
fig
see
color
insert
sister
chromatid
chromosom
passag
number
screen
metaphas
interphas
consist
integr
pigelaelb
one
chromosom
wherea
consist
integr
two
chromosom
number
copi
pigelaelb
present
chromosom
studi
southern
blot
analysi
dot
bot
analysi
fiber
fish
analysi
southern
hybrid
reveal
presenc
sever
integr
copi
pigelaelb
genom
addit
dot
blot
analysi
show
pigelaelb
plasmid
copi
number
ib
research
master
cell
bank
extend
cell
bank
passag
number
per
genom
result
conclud
consist
five
six
copi
pigelaelb
per
haploid
genom
fiber
fish
enabl
physic
length
measur
sywhybrid
dna
probe
linear
dna
fiber
resolut
equal
theoret
length
linear
dna
molecul
accord
model
watson
crick
kb
jxm
therefor
fiber
fish
conduct
measur
length
integr
construct
cell
line
passag
number
pn
twenti
fiber
measur
determin
pigelaelb
integr
tandem
copi
chromosom
copi
number
intandem
integr
determin
follow
cell
cellular
passag
harvest
chromosom
analysi
determin
modal
chromosom
number
karyotyp
sampl
metaphas
plate
cell
harvest
slide
prepar
stain
use
standard
giemsa
band
gtg
techniqu
passag
level
chromosom
metaphas
plate
count
also
full
karyotyp
prepar
passag
level
passag
level
chromosom
number
rang
mean
number
chromosom
modal
number
metaphas
plate
examin
structur
chromosom
chang
rearrang
marker
chromosom
addit
materi
long
arm
common
alter
found
metaphas
plate
karyotyp
passag
chromosom
number
rang
mean
number
chromosom
modal
number
metaphas
plate
karyotyp
found
structur
chang
common
chang
observ
karyotyp
also
marker
chromosom
extra
materi
short
arm
llp
karyotyp
marker
chromosom
addit
materi
short
arm
karyotyp
sever
marker
differ
two
passag
level
common
marker
continu
chang
seen
passag
level
increas
typic
heteroploid
continu
cell
line
cell
also
analyz
two
occas
dna
fingerprint
dna
profil
analysi
indic
chang
band
pattern
obtain
research
master
cell
bank
pn
extend
cell
bank
laid
passag
number
second
occas
consist
dna
fingerprint
obtain
pn
pn
evid
cross
contamin
cell
line
present
time
cell
line
best
substrat
product
adenovir
vector
gene
therapi
vaccin
conclus
base
abil
obtain
good
yield
safeti
consider
major
safeti
consider
possibl
product
replicationcompet
adeno
viru
rca
ii
tumorigen
risk
transform
cell
line
iii
presenc
abnorm
prion
iv
contamin
adventiti
agent
describ
chapter
lack
overlap
genom
adenovir
vector
carri
el
delet
adenovir
el
sequenc
carri
cell
make
homolog
recombin
imposs
therebi
prevent
format
rca
well
known
mani
transform
cell
line
produc
tumor
inject
immunodefic
anim
describ
cell
produc
tumor
nude
mice
cell
inject
produc
tumor
howev
cell
inject
sinc
anticip
cell
final
product
leav
question
possibl
tumorigen
residu
cellular
dna
studi
nude
mice
newborn
hamster
dna
cell
inject
neg
tumor
product
possibl
presenc
abnorm
prion
could
produc
neurodegen
diseas
also
consid
could
occur
cell
mutat
prion
gene
cell
contamin
abnorm
prion
bovin
spongioform
encephalopathi
far
possibl
serum
trypsin
batch
use
time
origin
cultur
trace
contact
serum
british
sourc
identifi
cell
line
also
adapt
serumfre
suspens
cultur
prion
protein
gene
cell
sequenc
mutat
found
cell
line
shown
heterozyg
polymorph
cell
line
also
analyz
presenc
abnorm
prion
earli
late
passag
earli
passag
parent
line
none
found
total
studi
indic
risk
prion
diseas
use
cell
vanishingli
small
final
extens
studi
known
unknown
adventiti
agent
document
neg
absolut
elimin
risk
bodi
studi
indic
minim
risk
use
cell
substrat
product
adenovir
vector
new
studi
develop
also
apph
ensur
hazard
present
often
point
continu
cell
line
permit
extens
analysi
adventiti
agent
safeti
concern
thu
less
hazard
shortliv
primari
cell
cultur
test
must
repeat
newli
establish
cultur
